

Державне підприємство
УКРАЇНСЬКИЙ ІНСТИТУТ
ІНТЕЛЕКТУАЛЬНОЇ ВЛАСНОСТІ
(УКРПАТЕНТ)

1 / 2 | в кошик | друк | результати пошуку | назад | дал

Бібліографічні дані до патенту на винахід # 25833
ЗАСІБ ДЛЯ ЛІКУВАННЯ МЕЛАНОМБЛАСТОМ

Бібліографічні дані	Реферат (uk)	Реферат (ru)	Реферат (en)	Опис
Патент України (на 20 р.)				патент не діє
(11) 25833	(51) МПК (2006) A61P 35/00			
(24) 26.02.1999	A61P 43/00			
(21) 94117468	(22) 04.11.1994			
(46) 26.02.1999, бюл. № 1				
(71) КУЛИК ІВАН ОНИСИМОВИЧ (UA)				
(72) Кулик Іван Онисимович (UA)				
(73) КУЛИК ІВАН ОНИСИМОВИЧ (UA)				
(54) ЗАСІБ ДЛЯ ЛІКУВАННЯ МЕЛАНОМБЛАСТОМ				
(57)				ВІДКРИТИ У НОВОМУ ВІКНІ

Применение таннина в качестве средства для лечения меланомбластом.

PATENT ON AN INVENTION #25833

A remedy for melanoblastoma treatment

Athor: KULIK IVAN ONISIMOVICH (UA)

Issued according to law of Ukraine "On Protection of Rights to Inventions and Utility Models"

Registered in the State Register of Patents of Ukraine for inventions 26 February 1999.

Head of the State Department of Intellectual Property

Ministry of Education and Science of Ukraine
State Department of Intellectual Property

DESCRIPTION OF THE PATENT № 25833

The invention relates to a herbal medicines and intended for the treatment of melanomblastoma (cancer).

The Aim of the invention is to find new medicine FLARAXIN with higher antitumor activity and low toxicity.

EXAMPLE 1

A mixture of tannin and potassium iodide at a ratio of 3:1, lyophilized, packaged in 20ml sterile vials and hermetically sealed.

During treatment of patients with melanomblastoms by new medicine that were dissolved in 5% glucose solution in the volume of 20ml and by 20 ml syringe were injected intravenously once a day. The course of treatment were 15 – 30 days intravenous administrations.

The effectiveness of the proposed remedy in comparison with Decarbonize and Polychemotherapy is illustrated below in a data table.

As can be seen from the table, FLARAXIN treatment efficiency is 90%, while Dacarbazine only 15-20% and Chemotherapy gives only 20 - 30%. Furthermore, Chemotherapeutic antineoplastic medicines all without exception, have a high degree of toxicity, resulting in the damage of organs, not only the tumor containing organs, but the

complex system damage that are not affected by the tumor. High toxicity limits the assignment of chemotherapy in particular, it is contra-indicated to the patients in terminal stages of the disease with neoplastic process. One persistent pathologies which limits the use of chemotherapy, damage of leukocyte blood sprout (germ) that causes persistent leukopenia.

The drug FLARAXIN refers to low-toxic compounds. Its use for the treatment of melanomoblastoms showed that it acts selectively on tumor process and has no effects on organs and systems. This allows applying FLARAXIN at different stages of the cancer disease, including the terminal stages.

Estimation of efficiency and toxicness of FLARAXIN with traditional preparations of chemotherapy for the melanoblastoma^{x/} treatment.

Medicine	Treatment efficiency, %	Toxicness, rate ^{xx/}				
		0	1	2	3	4
FLARAXIN	~ 90	-	+	-	-	-
Dacarbazine	15 – 20	-	-	-	+	+
Polychemotherapy: Nitrosomethylurea, Vincristine, Other complexes	20-30	-	-	-	+	+

Notes:

^{x/} Data of N.I.Perevodchikova (look the Antitumoralchemotherapy, Moscow, Medicine, 1986, p.36-37, 166).

^{xx/} 0 - absence of changes in the general condition and laboratory data;

1 – minimum changes not influencing on general activity of patient: laboratory data are changed insignificantly and does not require a correction.

2 – moderate changes, defiat normal activity and vital functions of patient, changes of laboratory indexes, requiring corrections.

3 - sharp violations, requiring active additional treatment, postponement or stopping of therapy;

4 - danger for life, after her liquidation it is possible to continue a chemotherapy only in considerably low dosages.